BCAX (Bicara Therapeutics) Buyback Yield %: -9.16 (As of Jun. 29, 2026)


BCAX Bicara Therapeutics Inc BCAX
12 GF Score
Price $28.01
! 3 Warning Signs
View Full Analysis

What is Bicara Therapeutics Buyback Yield %?

Bicara Therapeutics BCAX +4.24% 12 Buyback Yield % is -9.16 as of Jun. 29, 2026. GuruFocus rates BCAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 742 Biotechnology companies, Bicara Therapeutics ranks better than 50.13% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Bicara Therapeutics's current buyback yield was -9.16%.

Bicara Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Bicara Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicara Therapeutics Buyback Yield % Chart

Bicara Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Buyback Yield %
0.00 0.00 -35.05 -3.10

Bicara Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -3.10 -12.41

BCAX vs ZYME, SRPT, INVA: Buyback Yield % Comparison

For the Biotechnology subindustry, Bicara Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bicara Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Bicara Therapeutics's Buyback Yield % falls into.


BCAX
12GF Score
Bicara Therapeutics Inc BCAX
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bicara Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Bicara Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 29.498) / 952.59483
=-3.10%

Bicara Therapeutics's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 161.763) / 1303.72983
=-12.41%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -9.16 mean?
Bicara Therapeutics (BCAX) has a Buyback Yield % of -9.16 as of Jun. 29, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Bicara Therapeutics and its competitors. According to the industry distribution chart, Bicara Therapeutics ranks #370 out of 742 companies in the Biotechnology industry, placing it in the top 49.9%.
Is Bicara Therapeutics' Buyback Yield % too high?
Bicara Therapeutics' current Buyback Yield % is -9.16. Based on the distribution chart, Bicara Therapeutics ranks #370 out of 742 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bicara Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bicara Therapeutics' Buyback Yield % compare to ZYME and SRPT?
According to the Biotechnology industry distribution chart, Bicara Therapeutics ranks #370 out of 742 companies for Buyback Yield %. This puts Bicara Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Bicara Therapeutics and its competitors. Bicara Therapeutics's current Buyback Yield % is -9.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicara Therapeutics stock overvalued right now?
Bicara Therapeutics (BCAX) has a current Buyback Yield % of -9.16. The current Buyback Yield % is -9.16. Bicara Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Bicara Therapeutics (BCAX), the current Buyback Yield % is -9.16 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bicara Therapeutics Business Description

Address 116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
12GF Score

Get the complete analysis for BCAX

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.01
Price